Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | NAT1 | P18440 | 1/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005116 | 0.88 | ERN1 (0.52) | XDHERN1KDM4EPTGS2RAB9A | |
| SCHEMBL132439 | 0.83 | XDH (0.59) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL27935044 | 0.83 | XDH (0.59) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL24981909 | 0.83 | ERN1 (0.44) | XDHERN1KDM4EPTGS2RAB9A | |
| Water SCHEMBL36578 | 0.80 | XDH (0.57) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL31122716 | 0.80 | XDH (0.57) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL6740604 | 0.80 | ERN1 (0.45) | ERN1PTGS2TTRNAT1APP | |
| SCHEMBL28702107 | 0.78 | CHEK1 (0.46) | XDHERN1TTR | |
| SCHEMBL27426693 | 0.78 | KDM4E (0.52) | XDHERN1KDM4EPTGS2RAB9A | |
| SCHEMBL22991515 | 0.77 | TTR (0.39) | ERN1KDM4ETTRALDH1A1NAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0488860-B1 | Method for the production of polyalkoxylated aromatic compounds | RHONE POULENC CHIMIE (FR) | 1995-10-11 | — | — | EP | claimed |
| EP-0423010-B1 | METHOD FOR THE PRODUCTION OF ALKOXYBENZALDEHYDES | RHONE-POULENC CHIMIE (FR) | 1993-09-29 | — | — | EP | claimed |
| WO-2024135708-A1 | METHOD FOR PRODUCING COMPOUND, POLYMER, COMPOSITION, AND PATTERN FORMATION METHOD | 三菱瓦斯化学株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-2486026-B1 | DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER | MACGREGOR ALEXANDER (CA) | 2020-06-24 | — | — | EP | disclosed |
| EP-3101014-B1 | NOVEL 2-PHENYLBENZOFURAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY (KR) | 2019-03-13 | — | — | EP | disclosed |
| US-10053443-B2 | 2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2018-08-21 | — | — | US | disclosed |
| US-20170174645-A1 | 2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2017-06-22 | — | — | US | disclosed |
| EP-3101014-A1 | NOVEL 2-PHENYLBENZOFURAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Bioscience and Biotechnology (KR) | 2016-12-07 | — | — | EP | disclosed |
| US-20160332980-A1 | NOVEL 2-PHENYLBENZOFURAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-11-17 | — | — | US | disclosed |
| US-8895032-B2 | Dendritic nano-antioxidants | CENTRAL MICHIGAN UNIVERSITY (US) | 2014-11-25 | — | — | US | disclosed |
| US-6313305-B1 | ANTIBIOTICS, BACTERICIDES | HOECHST MARION ROUSSEL (FR) | 2001-11-06 | — | — | US | disclosed |
| US-5883248-A | QUATERNARY AMMONIUM INTERMEDIATES | ROUSSEL UCLAF (FR) | 1999-03-16 | — | — | US | disclosed |
| US-5763617-A | Cephalosporins | ROUSSEL UCLAF (FR) | 1998-06-09 | — | — | US | disclosed |
| CN-1178671-A | Method for preparing novel cephalosporin medicine composition containing substituted benzyloxy imino on the 7 th position | ROUSSEL UCLAF CO (FR) | 1998-04-15 | — | — | CN | disclosed |
| US-5728828-A | A 3-(3-CHLORO- OR IODOPROP-1-EN-1-YL),7-(2-AMINOTHIAZOL-4-YL) ((CARBOXY)(PHENYL)METHOXYIMINO)ACETAMIDO-3-CEPHEM; GRAMNEGATIVE AND -POSITIVE BACTERIA, ESP. ANTIBIOTIC-RESISTANCE STAPHYLOCOCCUS | ROUSSEL UCLAF (FR) | 1998-03-17 | — | — | US | disclosed |
| US-5712266-A | Cephalosporins | ROUSSEL UCLAF (FR) | 1998-01-27 | — | — | US | disclosed |
| US-5587372-A | BACERICIDES | ROUSSEL UCLAF (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5455238-A | Bactericides | ROUSSEL UCLAF (FR) | 1995-10-03 | — | — | US | disclosed |
| EP-0551034-A2 | Cephalosporins having in position 7 a benzyloxyimino radical substitute, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1993-07-14 | — | — | EP | disclosed |
| CN-1073177-A | Novel cephalosporins containing a substituted benzyloxyimino radical in position 7, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1993-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053443-B2 | 2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease | TNF, IL6, LITAF | XDH 386/4885ERN1 3995/4885KDM4E 1260/4885 |
| US-20170174645-A1 | 2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease | TNF, IL6, LITAF | XDH 386/4885ERN1 3995/4885KDM4E 1260/4885 |
| US-20160332980-A1 | NOVEL 2-PHENYLBENZOFURAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | TNF, IL6, LITAF | XDH 575/4885ERN1 3761/4885KDM4E 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.